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Abstract
This study presents the first characterization of carbapenem-non-susceptible Klebsiella
pneumoniae isolates by means of a structured six-month survey performed in Romania as
part of an Europe-wide investigation. Klebsiella pneumoniae clinical isolates from different
anatomical sites were tested for antibiotic susceptibility by phenotypic methods and con-
firmed by PCR for the presence of four carbapenemase genes. Genome macrorestriction
fingerprinting with XbaI was used to analyze the relatedness of carbapenemase-producing
Klebsiella pneumoniae isolates collected from eight hospitals. Among 75 non-susceptible
isolates, 65 were carbapenemase producers. The most frequently identified genotype
was OXA-48 (n = 51 isolates), eight isolates were positive for blaNDM-1 gene, four had the
blaKPC-2 gene, whereas two were positive for blaVIM-1. The analysis of PFGE profiles of
OXA-48 and NDM-1 producing K. pneumoniae suggests inter-hospitals and regional trans-
mission of epidemic clones. This study presents the first description of K. pneumoniae
strains harbouring blaKPC-2 and blaVIM-1 genes in Romania. The results of this study high-
light the urgent need for the strengthening of hospital infection control measures in Romania
in order to curb the further spread of the antibiotic resistance.
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Introduction
Carbapenemase-producing Enterobacteriaceae (CPE), notably Klebsiella pneumoniae, produce
serious infection (urinary tract infections, septicemia, pneumonia, and intra-abdominal infec-
tions) in debilitated and immunocompromised patients, in association with prolonged hospi-
talization and increased fatality ranging from 24% to 70%, depending on the study population
[1]. CPE are spreading globally as multidrug-resistant pathogens for which there are only few
treatment options available [1].
There are no national statistics in Romania regarding CPE or a national surveillance system
for CPE, but a national sentinel surveillance system for nosocomial infections including inva-
sive Klebsiella pneumoniae infections is operating. Also, as member of EARSNet, Romania is
reporting yearly the number of invasive K. pneumoniae isolates which are resistant to carbape-
nems, but not the mechanisms of resistance, including carbapenemase producing capacity or
type of enzyme. Clinical microbiology laboratories are currently performing the phenotypic
diagnostic of carbapenem-non-susceptible isolates. Voluntary some of them which are investi-
gating the carbapenemase-production capacity of K. pneumoniae isolates, are sending the
strains for confirmation and further characterization to National Expert Laboratory (NEL)
from Cantacuzino National Institute of Research-Development for Microbiology and Immu-
nology (Cantacuzino NIRDMI).
In Romania, little is known about the distribution and spread of carbapenemase-producing
Klebsiella pneumoniae, and the type of carbapenemases produced [2, 3, 4]. Only two studies
have been published about CPE strains in Romania [3,4]. First study is describing the local dis-
tribution of carbapenemase encoding genes (blaNDM-1, blaOXA-48 and blaOXA-181) in nine clini-
cal isolates collected in an emergency university hospital located in the center of Romania,
whereas the second study presents the distribution of CPE in two hospitals in Bucharest during
one year (2011–2012) [3, 4].
The present study was performed as part of the European Survey on Carbapenemase-Pro-
ducing Enterobacteriaceae (EuSCAPE) [2] aiming to provide a six-months snapshot about the
occurrence of the carbapenemase-producing K. pneumoniae isolated from clinical specimens
of individual patients in Romanian hospitals. Moreover, this study identified the type of carba-
penemase and determined the genomic diversity of carbapenemase-producing K. pneumoniae
using Pulsed Field Gel Electrophoresis (PFGE). The results of this study are expected to con-
tribute to a better understanding of the resistance genotype and geographical spread of carba-




According to EuSCAPE protocol each participating country should enroll a number of hospi-
tals in a geo-demographically representative manner, proportional with population size of the
country. Romania is divided in eight developmental zones: north-western, north-eastern, west-
ern, center, southwest, southern, southern-east and Bucharest.
A number of twelve hospitals from every developmental zone of the country, having labora-
tory capacity to detect carbapenem resistance were invited in September 2013 to participate to
the study. Six hospitals from Bucharest and two hospitals from Iasi and Bacau counties located
in the north-eastern part of the country contributed with isolates. The population catchment of
hospitals from capital city are comprising people living in Bucharest city but also in counties
from southern and southern-east zones of Romania.
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All hospitals participated on a voluntary basis to the project. During the six-month survey,
starting in November 2013 ending in April 2014 (according to the EuSCAPE protocol), each
hospital collected and dispatched the first 10 carbapenem-non-susceptible K. pneumoniae iso-
lates from single successive patients to the NEL at the Cantacuzino NIRDMI for species confir-
mation, and further phenotypic and genotypic characterization. Each hospital also sent to NEL
the information about the total number of K. pneumoniae isolates (both first successive non-
susceptible and susceptible to carbapenem) enrolled in the study as well as the total number of
isolates collected during the survey period (Table 1).
According to the protocol, the participating hospitals collected information about their bed
size, catchment populations and some epidemiological data, such as age and gender of the
patients, patient location within the hospitals (outpatient, normal ward, ICU), clinical rele-
vance of the isolate (colonization versus infection), hospital acquisition or community onset,
hospital admissions and history of travel during the previous six months.
Bacterial strains
Bacterial isolates from hospitalized patients were identified in the hospital diagnostic laborato-
ries using routine identification procedures [5], and antimicrobial susceptibility testing was
performed by the disk diffusion method.
Confirmation of carbapenem susceptibility
K. pneumoniae isolates were sent to the National Expert Laboratory and confirmed as carbape-
nem-non-susceptible by disk diffusion method using imipenem, meropenem and ertapenem
disks. Screening for carbapenemase production was performed by a combination of Kirby-
Bauer disk-diffusion methods according to the EUCAST guideline [6], MastDisc ID inhibitor
combination disks (MDI) (Mast Group Ltd, UK) and the biochemical Carba NP II tests based
on manufacturer’s instructions [7]. Moreover, a temocillin disk (30μg) was used for presump-
tive detection of OXA-48–like enzyme producers. MastDisc ID and Carba NP II were used for
phenotypic confirmation of carbapenemase, whereas PCR assays were used for their genetic
confirmation.
Table 1. Hospital origin, number and frequency of carbapenem-non-susceptibleK. pneumoniae isolates included in the study and total number of
carbapenem susceptible and non-susceptible isolates collected during survey period.
ID hospital number Municipality/ county Municipality/ county
population size
Number of beds Number of NSa isolates
sent to NRL
for the study
Total number of isolates
collected during survey
period
NS (%) Sb (%) NS + S
H1 Bucharest 1 883 000 530 10 30 (16) 152 (84) 182
H2 Bucharest 1 883 000 265 5 5 (8) 57 (92) 62
H3 Bucharest 1 883 000 1084 10 42 (19) 178 (81) 220
H4 Bucharest 1 883 000 740 9 22 (21) 83 (79) 105
H5 Bucharest 1 883 000 441 7 12 (13) 80 (87) 92
H6 Bucharest 1 883 000 718 10 48 (18) 212 (82) 260
H7 Bacău 616 000 1182 12 52 (23) 172 (77) 224
H8 Iasi 772 300 1128 12 62 (26) 180 (74) 242
acarbapenem-non-susceptible isolates (NS)
bcarbapenem susceptible isolates (S)
doi:10.1371/journal.pone.0143214.t001
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Molecular detection and genetic characterization of carbapenemase
encoding genes
Screening for the presence of most clinically relevant K. pneumoniae carbapenemases accord-
ing to the EuSCAPE protocol was performed by amplification of the genes blaOXA-48-like,
blaNDM, blaKPC and blaVIM using PCR primers described in Table 2.
Total genomic DNA from 75 carbapenem-non-susceptible K. pneumoniae strains used in
all PCR assays was obtained by thermal lysis (boiling a fresh cultured colony in 200 μl distilled
water and subsequent centrifugation at 14,000 rpm).
For further characterization of genes encoding NDM, VIM and KPC carbapenemases a sec-
ond PCR was performed with specific primers (Table 2). For OXA-48-like carbapenemase the
same primers used for PCR screening were used for sequencing. Obtained amplified products
were sequenced using BigDye Terminator v 3.1 and 3100 Avant Genetic Analyser (Applied
Biosystems). The sequences were edited and aligned using the BioEdit version 7.0.5.3. software
package.
The genetic relatedness among carbapenem-non-susceptible isolates was evaluated using
PFGE analysis according to the standard protocol designed by the Centre for Disease Control
and Prevention Atlanta (http://www.cdc.gov/pulsenet/pathogens/index.html), and recom-
mended within the ECDC study project for molecular typing of bacteria involved in food and
water diseases (FWD) [14]. PFGE of XbaI-digested total DNA was performed as described for
E. coli. PFGE profiles were compared using BioNumerics v 5.1. We defined a PFGE type based
on a similarity cut-off of 80% (Dice coefficient, represented by UPGMA, 1.5% optimization
and 1.5% tolerance). Different PFGE types were given in alphabetical order. Every band differ-
ence within a PFGE type resulted in a subtype which was given a numerical order.
Ethics Statement
Informed written consent was obtained from all participants in this study after explanation of
the procedure and the purpose of the study. The study was approved by the review boards of
the Research Ethics Committee, Cantacuzino National Institute of Research-Development for
Microbiology and Immunology.
Table 2. Primers used for screening, confirmation and sequencing of carbapenemase encoding genes.
Target
gene




blaOXA-48-like OXA-F OXA-R TTGGTGGCATCGATTATCGG GAGCACTTCTTTTGTGATGGC 744 [8]
blaNDM NDM-F NDM-R TGGCAGCACACTTCCTATC AGATTGCCGAGCGACTTG 488 [Miriagou,
unpublished]
blaKPC KPC-F KPC-R CTGTCTTGTCTCTCATGGCC CCTCGCTGTRCTTGTCATCC 796 [9]
blaVIM VIM-F VIM-R AGTGGTGAGTATCCGACAG TCAATCTCCGCGAGAAG 212 [10]








ATGTCACTGTATCGCCGTCT TTTTCAGAGCCTTACTGCCC 883 [12]
blaVIM VIM-Fseq VIM-Rseq GTTTGGTCGCATATCGCAAC AATGCGCAGCACCAGGATAG 801 [13]
doi:10.1371/journal.pone.0143214.t002
Carbapenemases in Romania
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Results
Bacterial isolates
All the 75 isolates preliminarily identified in the hospital laboratories participating in the
EuSCAPE project were confirmed as K. pneumoniae by the National Expertise Laboratory in
Cantacuzino NIRDMI. They originated from different anatomical sites: urine (n = 39), lower
respiratory tract (n = 17), blood (n = 13), wound (n = 4), puncture sites (n = 1) and peritoneum
(n = 1).
About 51% of carbapenemase-producing isolates were from patients with hospital-acquired
infections, 26% had a community onset, whereas for 23% the epidemiological context was
unknown. The history of previous hospitalization and travel remained unknown for all
patients.
Phenotypic characterization of carbapenem-non-susceptibility
The results of the Kirby-Bauer disk-diffusion method showed that 72 (96%) of K. pneumoniae
isolates were resistant to ertapenem, 40 (50.3%) exhibited meropenem resistance, whereas only
8 (10.7%) of the isolates were imipenem resistant.
Phenotypic tests for carbapenemase detection showed that 65 out of 75 carbapenem-non-
susceptible isolates contained one of three Ambler classes of carbapenemase, A (KPC-type), B
(metallo-beta-lactamase—MBL) or D (OXA-type), whereas for 10 isolates no carbapenemase
activity was detected.
For 51 isolates, testing for temocillin susceptibility showed absence of inhibition zones in
the disk diffusion test (disk load 30μg) indicative of OXA-48-like carbapenemase. MastDisc ID
and Carba NP II identified 10 isolates positive for class B carbapenemase, 4 isolates as class A
carbapenemase producers, whereas the remaining 51 carbapenemase-producing isolates could
be suspected as class D carbapenemase producers.
Genetic confirmation of carbapenemase-producing isolates
Distribution of genes encoding carbapenemases among carbapenemase-producing iso-
lates. The PCR results showed that 51 strains harbored the blaOXA-48-like gene, 8 strains had
the blaNDM gene, whereas the blaKPC and blaVIM genes were present in 4 and 2 strains,
respectively.
blaOXA-48-like gene positive K. pneumoniae isolates were identified in all hospitals, while
blaNDM was detected in half and blaKPC and blaVIM were identified in only three and one of the
participating hospitals, respectively (Table 3). Among the remaining 10 carbapenem-non-sus-
ceptible isolates none of the four carbapenemase target genes were detected.
The sub-type of carbapenemase genes among carbapenemase-producing isolates. DNA
sequencing allowed for an identification of the sub-type of the respective carbapenemase genes
in all carbapenemase-producing K. pneumoniae isolates. Thus, all sequenced KPC producers’
harboured blaKPC-2 genes, whereas all OXA-48-like producers had a blaOXA-48 gene. All NDM
producers had a blaNDM-1 gene, whereas all VIM producers carried the blaVIM-1 gene.
The genetic relatedness among carbapenemase-producing isolates. The analysis of
PFGE results of the 65 carbapenemase-producing K. pneumoniae isolates identified 8 PFGE
types (i.e. A-H) (Fig 1). The most frequent type was C, which consisted of 35 isolates subdi-
vided into 17 PFGE subtypes (i.e. C1-C17) followed by G with 16 isolates with 13 subtypes (i.e.
G1-G13) (Fig 1). Most OXA-48 producers, 47 (92%) isolates had these genotypes. The minor
types (i.e. A, B, D, E, F, and H) included between 1 and 4 isolates each. Among them, type E
was exclusively represented by KPC-2-positive isolates.
Carbapenemases in Romania
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Discussion
This is the first systematic multi-centre study describing the occurrence of carbapenem-non-
susceptible K. pneumoniae isolates and their genetic resistance determinants responsible for
carbapenemase production in Romania.
Our study shows that OXA-48 carbapenemase has been the most prevalent carbapenemase
during the study period, being detected in 79% of carbapenemase-producing K. pneumoniae
isolates in Romanian hospitals. Importantly, strains that produce this carbapenemase were
spreading among all participating hospitals in this study. OXA-48 had first been identified
from a clinical K. pneumoniae isolate recovered in Istanbul, Turkey, in 2001 [15]. For several
years, OXA-48 appeared to be confined to Turkey, as almost all OXA-48 beta-lactamase pro-
ducers were reported either among patients hospitalized in Turkey or with a link to that coun-
try [16, 17]. Since 2008, this carbapenemase has been identified in many other countries,
mainly in K. pneumoniae [15, 17]. In addition to sporadic cases, an increasing number of out-
breaks due to OXA-48-producing K. pneumoniae are currently reported, not only in Turkey
but also in Belgium, France, Greece, the Netherlands and Spain [15, 17–20]. The successful
spread of OXA-48 producers is now considered an epidemic threat as it represents an impor-
tant source of multidrug resistance in K. pneumoniae in Europe [21, 22].
In Romania the presence of OXA-48 producing K. pneumoniae isolates has only occasion-
ally been reported. The first study published was conducted between January 2010 and Septem-
ber 2012 in an emergency university hospital from the central part of Romania, where three K.
pneumoniae ST101 isolates with indistinguishable PFGE profiles were reported [3]. The second
study was performed between October 2011 and November 2012 in two hospitals in Bucharest,
which identified 31 patients with K. pneumoniae isolates harbouring blaOXA-48 gene [4]. No
typing results were reported.
In the present study PFGE analysis of the 51 OXA-48 producing K. pneumoniae strains
showed that 47 out of 51 (92%) strains isolated from all hospitals belonged to the same epi-
demic clone, whereas the remaining four isolates had different PFGE profiles. These results
suggest an epidemic expansion of a major OXA-48 positive clone which evolves hospitals in
different regions of the country.
We also identified eight K. pneumoniae isolates harbouring the blaNDM-1 gene. This gene
may be carried by different plasmid types, most of them co-harboring multiple but variable
resistance determinants [23]. A few plasmids carrying blaNDM-1 also encode other carbapene-
mases, including OXA-181- and VIM-types [24]. The first New Delhi metallo-beta-lactamase
(NDM-1) producing strains detected in Europe were associated with importation from the
Table 3. Distribution of carbapenemase-producing isolates according to hospital of isolation.
Hospital Number carbapenems- non-susceptible Number carbapenemase producers Type of carbapenemase
OXA-48 NDM KPC VIM
H1 10 8 6 2 - -
H2 5 5 4 1 - -
H3 10 8 4 2 2 -
H4 9 8 7 - 1 -
H5 7 6 5 - 1 -
H6 10 9 9 - - -
H7 12 10 8 - - 2
H8 12 11 8 3 - -
Total 75 65 51 8 4 2
doi:10.1371/journal.pone.0143214.t003
Carbapenemases in Romania
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Indian subcontinent. More recently, countries in the Balkan region (Serbia, Montenegro, Bos-
nia and Herzegovina) also reported patients infected and colonized with NDM-1 producers
[23, 25–26]. In Romania, the presence of this enzyme among K. pneumoniae was recognized
previously [3, 4]. In addition, anecdotal reports suggested the introduction of NDM-1 produc-
ing strains by travelers into Romania [27]. Their PFGE profiles exhibited a 80% similarity,
indicative of a single clone, expanding within and between four hospitals from different Roma-
nian regions. According to an international staging system [28] Romania thus would assume
an epidemiological stage 4 for both OXA-48 and NDM-1 producing K. pneumoniae.
We also found isolates producing VIM-1 as well as KPC-2 carbapenemase. Strains with
these types had previously not been identified in Romania. The PFGE profiles of two VIM-1
positive strains collected from patients hospitalized in the same hospital (H7) were seemingly
different, showing a similarity< 80%. The PFGE profiles of four K. pneumoniae isolates har-
bouring blaKPC-2 gene were however rather similar, with similarity ranging from 90% to 98%,
being part of the epidemic clone, showing both intra- and inter-hospitals (H3, H4 and H5 hos-
pitals) transmission.
The PFGE results of this study are testimony of a clonal dissemination of K. pneumoniae
harbouring all of the four carbapenemase genes across the sample of Romanian hospitals
Fig 1. PFGE profiles of 65 carbapenemase-producingKlebsiella pneumoniae isolates.
doi:10.1371/journal.pone.0143214.g001
Carbapenemases in Romania
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which have been enrolled and bears the hallmark of a much larger i.e. national epidemic of car-
bapenemase-producing Enterobacteriaceae in Romanian hospitals.
Hospitalized patients from whom the carbapenemase-producing K. pneumoniae isolates
were collected where kept in contact isolation according to guideline regarding prevention of
hospital infection transmission.
The results of PCR tests performed on 10 carbapenem resistant strains with no carbapene-
mase type detected by phenotypic tests showed that in these strains none of the carbapenemase
targeted genes were detected, suggesting that other resistance mechanisms to carbapenems
(ESBLS or AmpC β-lactamases combined with the loss of outer membrane porins OmpK35
and/or OmpK36) could have been involved [29, 30]. It could also be possible that carbapene-
mases other than those included in this study may have caused resistance in these isolates. But
this seems unlikely given the negative results of our phenotypic confirmation tests and the scar-
city with which other carbapenemases are reported in Europe. These results demonstrate the
importance of molecular tests in the confirmation of carbapenemase-producing Klebsiella
pneumoniae.
Limitations of the study
This study has several limitations regarding the rate of response of 67% of invited hospitals par-
ticipating in the survey as well as the time of only six months. Although hospitals were invited
in a geo-demographically representative manner the selection bias could occur due to the fact
that participating hospitals in the survey were those having a catchment population for coun-
ties from southern, southern-east, north-eastern and Bucharest zones of Romania and obtained
data could be extrapolated only for those zones. Clinical data of the isolates as well as data on
antibiotic consumption are not presented in this study.
Conclusions
This study shows the first detection of K. pneumoniae strains harbouring blaKPC-2 and blaVIM-1
genes in Romania. The carbapenemase most frequently detected is OXA-48, representing 79%
of carbapenemase-producing K. pneumoniae strains. This carbapenemase was detected in iso-
lates collected from patients hospitalized in all of the participating hospitals, and the PFGE
results suggest the spread of a single clone in all sampled hospitals with outbreaks in two of
them. Likewise, NDM-1 positive strains have also been identified in four hospitals and PFGE
results indicate a similar epidemic dynamic as for OXA-48. Based on these findings Romania
would assume a epidemiological stage 4 for OXA-48 and NDM-1 carbapenemases according
to an international staging system.
Before starting this survey by self-assessment realized by the national expert in March 2013,
the epidemiological stage 1 was established for carbapenemase-producing isolates from Roma-
nia. The present study allowed updating and upgrading the epidemiological stages for all inves-
tigated carbapenemases.
The results of this study show that for efficient monitoring of the rapidly evolving spread of
carbapenemase-producing K. pneumoniae the development of a national management system
for CPE through a dedicated surveillance program, the provision of references services, the
obligation to notify cases to health authorities and a national plan for containment of/or pre-
paredness to contain CPE are necessary. In addition European Council Recommendation of 15
November 2001 [31] on the prudent use of antimicrobial agents in human medicine should
strongly be considered including Strategies towards sufficient surveillance systems on usage of
antibiotics and antimicrobial resistance, control and preventive measures, promoting educa-
tion and training of health care workforce and inform the general public.
Carbapenemases in Romania
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